SCHEMBL31069764

SCHEMBL31069764

COCCOc1ccc(C(N)=O)c(F)c1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 5/20 0.59
PARP14 Q460N5 1/20 0.59
PARP15 Q460N3 3/20 0.57
CHEK1 O14757 2/20 0.49
CHEK2 O96017 1/20 0.46
DGAT1 O75907 1/20 0.46
MAPK14 Q16539 1/20 0.46
GPR119 Q8TDV5 1/20 0.46
MAOB P27338 3/20 0.46
RARA P10276 1/20 0.44
RARB P10826 1/20 0.44
MAOA P21397 1/20 0.44
AURKA O14965 1/20 0.42
RPS6KB1 P23443 1/20 0.42
CPS1 P31327 1/20 0.42
CRBN Q96SW2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3849764 0.86 MAOB (0.61) MAPK14MAOBRARARARBMAOA
SCHEMBL5469298 0.84 PARP10 (0.59) PARP10PARP14PARP15DGAT1GPR119
SCHEMBL31069762 0.84 PARP10 (0.59) PARP10PARP14PARP15DGAT1GPR119
SCHEMBL12116990 0.83 CHEK1 (0.50) CHEK1CHEK2MAOB
SCHEMBL3079256 0.83 PARP10 (0.58) PARP10PARP14PARP15DGAT1GPR119
SCHEMBL22286220 0.82 MAOB (0.44) PARP10PARP14PARP15MAPK14MAOB
SCHEMBL26028477 0.82 PARP10 (0.54) PARP10PARP14PARP15DGAT1GPR119
Hydrochloric Acid SCHEMBL30779145 0.81 PARP10 (0.59) PARP10PARP14PARP15DGAT1GPR119
SCHEMBL72082 0.80 CPS1 (0.61) PARP10PARP14PARP15DGAT1CPS1
SCHEMBL10468411 0.80 CHEK1 (0.50) PARP10CHEK1CHEK2MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240382457-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS PHARMA AG (CH) 2024-11-21 US disclosed
US-12083101-B2 Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors NOVARTIS AG (CH) 2024-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12083101-B2 Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors YAP1, TEAD3, TEAD2 PARP10 653/4885PARP14 1322/4885PARP15 444/4885
US-20240382457-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS YAP1, TEAD3, TEAD2 PARP10 653/4885PARP14 1322/4885PARP15 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.